Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.
Schützinger
C
C
Gaiger
A
A
Thalhammer
R
R
Vesely
M
M
Fritsche-Polanz
R
R
Schwarzinger
I
I
Ohler
L
L
Simonitsch-Klupp
I
I
Reinhard
F
F
Jäger
U
U
D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019676:Genes, T-Cell Receptor delta; D019675:Genes, T-Cell Receptor gamma; D006801:Humans; D015458:Leukemia, T-Cell / Q000150:complications*; D008297:Male; D012010:Red-Cell Aplasia, Pure / Q000188:drug therapy* / Q000209:etiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab